Navigation Links
Study confirms 2 vaccine doses protect children from chickenpox
Date:1/4/2011

[EMBARGOED FOR JAN. 5, 2011] Two doses of the varicella, or chickenpox, vaccine provide excellent protection in children against this highly contagious and, in some cases, severe disease. To be published in the February 1 issue of The Journal of Infectious Diseases, the findings support the two-dose vaccine regimen recommended in the United States since 2006. (Please see below for a link to the study online.)

The Centers for Disease Control and Prevention (CDC) began recommending a single dose of varicella vaccine in children aged 1 to 13 years old in 1995. Although the incidence of varicella fell by 90 percent after introduction of the vaccine, there was a high rate of breakthrough varicella illness in immunized children and continuing outbreaks of varicella among children despite high rates of vaccination. Studies also showed that the single-dose vaccine's effectiveness was less than 90 percent. Given the evidence, CDC in 2006 began recommending a second dose of the vaccine for children 4 to 6 years old.

Although data suggest that two doses of varicella vaccine are associated with higher levels of antibody than is one dose, this study is the first to assess the clinical effectiveness of two doses of the vaccine in the general population. Eugene D. Shapiro, MD, and colleagues at Yale University and collaborators at Columbia University conducted active surveillance in an area in Connecticut and discovered 71 cases of varicella in children aged 4 or older. None of the children had received two doses of vaccine, 66 (93 percent) had received one dose, and 5 (7 percent) had received no vaccine.

The investigators then compared the effectiveness of two doses of vaccine versus one dose in a case-control study, using 140 matched controls. The effectiveness of one dose in preventing varicella was 86.0 percent, while the effectiveness of two doses was 98.3 percent. According to Dr. Shapiro, "The odds of developing varicella were 95 percent lower in children who had received two doses of the vaccine compared with those who had received only one."

The results of this study suggest that countries immunizing children with only one dose of varicella vaccine should consider changing to a two-dose regimen. But, the authors emphasized, "There should be continued monitoring of the effectiveness of two doses to assure that its high degree of effectiveness is sustained."

In an accompanying editorial, David W. Kimberlin, MD, of the University of Alabama at Birmingham, agreed with the study authors, noting that this study is the first to evaluate the effectiveness of two doses of varicella vaccine in a "real-world" setting. "The high effectiveness of 98.3 percent found in this investigation supports the programmatic change instituted four years ago," Dr. Kimberlin noted.

Fast Facts:

1) In this study, the odds of developing varicella (chickenpox) were 95 percent lower in children > 4 years of age who had received two doses of the varicella vaccine compared with those who had received only one dose.

2) Of the 71 cases of varicella noted in the study, none of the subjects had received two doses of vaccine.

3) The effectiveness of two doses of vaccine in protecting against varicella in the study population was 98.3 percent.


'/>"/>

Contact: John Heys
jheys@idsociety.org
703-299-0412
Infectious Diseases Society of America
Source:Eurekalert

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. TV drama can be more persuasive than news program, study finds
4. Study carried out into biological risks of eating reptiles
5. Neuroimaging study may pave way for effective Alzheimers treatments
6. Study finds racial gaps continue in heart disease awareness
7. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Soothing infants with food focus of childhood obesity study
10. People with anxiety disorder less able to regulate response to negative emotions, study shows
11. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... KING OF PRUSSIA, PA and LONDON, UK (PRWEB) , ... May ... ... continues to earn accolades for his success in changing the way the pharmaceutical industry ... Power 100 list of the world’s most influential people in pharma, and he was ...
(Date:5/6/2016)... Chandler, AZ (PRWEB) , ... May 06, 2016 ... ... No Greater Odds, are scheduled to provide a unique keynote address at the ... documentary follows the inspirational stories of five community college students. Their stories—of complicated ...
(Date:5/6/2016)... ... ... A wide variety of national pet product manufacturers, companies and brands will gather for one ... 18 from noon to 8 p.m. at New York City’s Roger Smith Hotel. The event ... garden, outdoor and safety pet products in today’s marketplace. , Petrend Event showcases ...
(Date:5/6/2016)... Jupiter, FL (PRWEB) , ... May 06, 2016 ... ... it will feature AsedaSciences® in an upcoming episode, airing third quarter 2016, via ... with the vision of becoming a leader in optimized drug discovery through innovative ...
(Date:5/6/2016)... Pass, OR (PRWEB) , ... May 06, 2016 , ... ... eyes. In other seasons, when the weather is too cold, dry or hot, water ... the eyes can actually absorb moisture from the surrounding air. There’s only one problem, ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... ZIONA, Israel , May 4, ... TASE: BVXV) announced today that BiondVax,s CEO, Dr. Ron ... conference in New York City . ... at 10:30am at Pioneers 2016, a conference presented by ... York Palace Hotel. The BiondVax presentation that Dr. ...
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... , May 4, 2016 ... completion of an alternative public offering (APO). This was ... operating company, Valeritas, Inc. and a private placement of ... at $5.00 per share. Under the terms ... 3, 2016, Valeritas Holdings, Inc. will trade on the ...
Breaking Medicine Technology: